

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Lorlatinib (Lorbrena)

Initiation (new start) criteria: Non-formulary **lorlatinib (Lorbrena)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by an oncologist or hematologist
 - Diagnosis of anaplastic lymphoma kinase (ALK)- positive, metastatic, non-small cell lung cancer
 - Patient progressed on first-line crizotinib and at least one other ALK inhibitor (alectinib, certinib, or brigatinib)
- OR-**
- Patient progressed on alectinib or certinib as the first ALK inhibitor therapy for metastatic disease